These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26192075)

  • 1. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
    Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
    Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Cell- and Tissue-Based Therapeutic Products in Singapore.
    Kellathur SN
    Tissue Eng Part A; 2015 Dec; 21(23-24):2802-5. PubMed ID: 26096855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea.
    Lim JO
    Tissue Eng Part A; 2015 Dec; 21(23-24):2791-6. PubMed ID: 25759938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premarket Regulation of Tissue Engineered Medical Products in China.
    Wang C; Wang A; Feng X; Ke L; Huang Y; Han Q; Sun X; Yang Z
    Tissue Eng Part A; 2015 Dec; 21(23-24):2806-11. PubMed ID: 26529310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation Policy for Cell and Tissue Therapies in Australia.
    Sturm M
    Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovative regenerative medicines in the EU: a better future in evidence?
    Corbett MS; Webster A; Hawkins R; Woolacott N
    BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation Policy on Tissue Engineering and Regenerative Medicine in Asian-Pacific Region.
    Liu W; Burdick JA; van Osch GJ
    Tissue Eng Part A; 2015 Dec; 21(23-24):2779-80. PubMed ID: 26486210
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory biocompatibility requirements for biomaterials used in regenerative medicine.
    Williams DF
    J Mater Sci Mater Med; 2015 Feb; 26(2):89. PubMed ID: 25649511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Oversight of Cell and Gene Therapy Products in Malaysia.
    Loh EYX; Ab Ghani A; Ahmad R
    Adv Exp Med Biol; 2023; 1430():181-195. PubMed ID: 37526848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Same but Different: Regulation of Tissue Engineering and Regenerative Medicine in the Context of Regional and International Standards and Expectations.
    Williams DF
    Tissue Eng Part A; 2015 Dec; 21(23-24):2781-2. PubMed ID: 26486499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From in vitro to in situ tissue engineering.
    Sengupta D; Waldman SD; Li S
    Ann Biomed Eng; 2014 Jul; 42(7):1537-45. PubMed ID: 24809723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The early career researcher's toolkit: translating tissue engineering, regenerative medicine and cell therapy products.
    Rafiq QA; Ortega I; Jenkins SI; Wilson SL; Patel AK; Barnes AL; Adams CF; Delcassian D; Smith D
    Regen Med; 2015 Nov; 10(8):989-1003. PubMed ID: 26628407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Supervision, administration and standard research related to tissue engineered medical products].
    Xi TF; Chen L; Zhao P
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2003 Nov; 17(6):480-7. PubMed ID: 14663949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncertain Oversight of Regenerative Medicines in Japan under the ASRM.
    Lysaght T; Sugii S
    Cell Stem Cell; 2016 Apr; 18(4):438-9. PubMed ID: 27058936
    [No Abstract]   [Full Text] [Related]  

  • 16. Accelerating Cell Therapy for Stroke in Japan: Regulatory Framework and Guidelines on Development of Cell-Based Products.
    Houkin K; Shichinohe H; Abe K; Arato T; Dezawa M; Honmou O; Horie N; Katayama Y; Kudo K; Kuroda S; Matsuyama T; Miyai I; Nagata I; Niizuma K; Sakushima K; Sasaki M; Sato N; Sawanobori K; Suda S; Taguchi A; Tominaga T; Yamamoto H; Yamashita T; Yoshimine T;
    Stroke; 2018 Apr; 49(4):e145-e152. PubMed ID: 29581346
    [No Abstract]   [Full Text] [Related]  

  • 17. Balancing Safety and Innovation for Cell-Based Regenerative Medicine.
    Marks P; Gottlieb S
    N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023
    [No Abstract]   [Full Text] [Related]  

  • 18. Governmental Regulations and Increasing Food and Drug Administration Oversight of Regenerative Medicine Products: What's New in 2020?
    Fang WH; Vangsness CT
    Arthroscopy; 2020 Oct; 36(10):2765-2770. PubMed ID: 32442713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA and NIST collaboration on standards development activities supporting innovation and translation of regenerative medicine products.
    Arcidiacono JA; Bauer SR; Kaplan DS; Allocca CM; Sarkar S; Lin-Gibson S
    Cytotherapy; 2018 Jun; 20(6):779-784. PubMed ID: 29784433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concise review: guidance in developing commercializable autologous/patient-specific cell therapy manufacturing.
    Eaker S; Armant M; Brandwein H; Burger S; Campbell A; Carpenito C; Clarke D; Fong T; Karnieli O; Niss K; Van't Hof W; Wagey R
    Stem Cells Transl Med; 2013 Nov; 2(11):871-83. PubMed ID: 24101671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.